ES2862922T7 - Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta - Google Patents

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta Download PDF

Info

Publication number
ES2862922T7
ES2862922T7 ES17823190T ES17823190T ES2862922T7 ES 2862922 T7 ES2862922 T7 ES 2862922T7 ES 17823190 T ES17823190 T ES 17823190T ES 17823190 T ES17823190 T ES 17823190T ES 2862922 T7 ES2862922 T7 ES 2862922T7
Authority
ES
Spain
Prior art keywords
seq
amino acid
sclerostin antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17823190T
Other languages
English (en)
Spanish (es)
Other versions
ES2862922T3 (es
Inventor
Uwe Junker
Michaela Kneissel
Anthony Kent Hall
Rena Joy Eudy
Matthew Manning Riggs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 3 Ltd
Original Assignee
Mereo Biopharma 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Ltd filed Critical Mereo Biopharma 3 Ltd
Application granted granted Critical
Publication of ES2862922T3 publication Critical patent/ES2862922T3/es
Publication of ES2862922T7 publication Critical patent/ES2862922T7/es
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES17823190T 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta Active ES2862922T7 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437353P 2016-12-21 2016-12-21
PCT/GB2017/053850 WO2018115880A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
ES2862922T3 ES2862922T3 (es) 2021-10-08
ES2862922T7 true ES2862922T7 (en) 2025-02-26

Family

ID=60915566

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17823190T Active ES2862922T7 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Country Status (23)

Country Link
US (5) US20200179509A1 (enExample)
EP (2) EP3868780A1 (enExample)
JP (3) JP7050335B2 (enExample)
KR (3) KR20240113615A (enExample)
CN (2) CN117442720A (enExample)
AU (1) AU2017381433B2 (enExample)
BR (1) BR112019012731A2 (enExample)
CA (1) CA3047221A1 (enExample)
CL (1) CL2019001749A1 (enExample)
CY (1) CY1124238T1 (enExample)
DK (1) DK3478719T6 (enExample)
ES (1) ES2862922T7 (enExample)
FI (1) FI3478719T6 (enExample)
HR (1) HRP20210207T4 (enExample)
HU (1) HUE053436T2 (enExample)
IL (1) IL267430B2 (enExample)
LT (1) LT3478719T (enExample)
MX (1) MX2019007161A (enExample)
NZ (1) NZ754676A (enExample)
PL (1) PL3478719T6 (enExample)
PT (1) PT3478719T (enExample)
SI (1) SI3478719T2 (enExample)
WO (1) WO2018115880A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HRP20260414T1 (hr) 2018-03-30 2026-05-08 Amgen Inc. C-terminalne varijante protutijela
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
MA55593A (fr) 2019-04-11 2022-02-16 Janssen Pharmaceutica Nv Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
MX2024003828A (es) * 2021-09-30 2024-05-10 Mereo Biopharma 3 Ltd Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta.
TW202606715A (zh) * 2024-04-05 2026-02-16 美商安進公司 治療成骨不全之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
KR101123487B1 (ko) * 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
BR112012026098A2 (pt) * 2010-04-16 2016-11-22 Novartis Ag métodos e composições para melhorar a osseointegração de implante.
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.

Also Published As

Publication number Publication date
IL267430B2 (en) 2026-01-01
IL267430A (en) 2019-08-29
CA3047221A1 (en) 2018-06-28
US20200179509A1 (en) 2020-06-11
JP2022046529A (ja) 2022-03-23
EP3478719A1 (en) 2019-05-08
KR20220051269A (ko) 2022-04-26
WO2018115880A1 (en) 2018-06-28
HRP20210207T1 (hr) 2021-03-19
KR20190096409A (ko) 2019-08-19
IL267430B1 (en) 2025-09-01
US20230365669A1 (en) 2023-11-16
DK3478719T3 (da) 2021-03-01
ES2862922T3 (es) 2021-10-08
CY1124238T1 (el) 2022-07-22
RU2019118719A3 (enExample) 2021-06-01
CL2019001749A1 (es) 2019-12-27
EP3478719B3 (en) 2024-12-18
BR112019012731A2 (pt) 2019-11-26
NZ754676A (en) 2023-06-30
US20240400666A1 (en) 2024-12-05
CN110325548B (zh) 2023-11-17
CN110325548A (zh) 2019-10-11
AU2017381433A1 (en) 2019-07-04
US20200123242A1 (en) 2020-04-23
JP2020502219A (ja) 2020-01-23
PL3478719T6 (pl) 2025-01-27
FI3478719T6 (fi) 2025-01-20
DK3478719T6 (da) 2025-01-20
SI3478719T1 (sl) 2021-09-30
MX2019007161A (es) 2020-02-12
JP2025020150A (ja) 2025-02-12
LT3478719T (lt) 2021-04-12
EP3868780A1 (en) 2021-08-25
PT3478719T (pt) 2021-03-18
HUE053436T2 (hu) 2021-06-28
AU2017381433B2 (en) 2024-11-14
EP3478719B1 (en) 2021-01-20
RU2019118719A (ru) 2021-01-22
US20210253684A1 (en) 2021-08-19
CN117442720A (zh) 2024-01-26
PL3478719T3 (pl) 2021-10-25
JP7050335B2 (ja) 2022-04-08
HRP20210207T4 (hr) 2025-01-31
SI3478719T2 (sl) 2025-07-31
KR20240113615A (ko) 2024-07-22

Similar Documents

Publication Publication Date Title
ES2862922T3 (es) Uso de anticuerpos antiesclerostina en el tratamiento de la osteogénesis imperfecta
US20250122273A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP6353500B2 (ja) Ｄｋｋ１抗体およびその使用方法
ES3040805T3 (en) The effective and efficient control of serum phosphate for optimal bone formation
NZ789250A (en) Use of myostatin inhibitors and combination therapies
PT2625199T (pt) Métodos de tratamento de psoríase usando antagonistas de il-17
ES2592628T3 (es) Terapia dirigida al receptor del factor de crecimiento epidérmico (EGFR)
KR20170045240A (ko) 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
US20210198350A1 (en) Use of a sclerostin antagonist
HK40058082A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR20240018471A (ko) 중등증 내지 중증 불완전 골형성증의 치료
CA3233220A1 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
HK40007021A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
HK40007021B (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
TW202346345A (zh) 面肩胛肱肌失養症（ｆｓｈｄ）之新治療
HK40050327A (en) Use of a sclerostin antagonist